Jan 31 | News
Biogen Idec Inc., a global biotechnology company contentrating on the discovery, development, manufacturing and commercialization of innovative therapies, today announced its full year and fourth quarter 2011 results.
|
Jan 4 | News
Biogen Idec and Isis Pharmaceuticals, Inc. today announced that they have entered into an exclusive, worldwide option and collaboration agreement under which the companies will develop and commercialize Isis’ antisense investigational drug, ISIS-SMNRx, for the treatment of spinal muscular atrophy (SMA).
|
Dec 6 2011 | News
Samsung and Biogen Idec today announced that they have entered into an agreement to invest $300 million to establish a joint venture to develop, manufacture and market biosimilars. Samsung will take a leading role in the joint venture, with Biogen Idec contributing its expertise in protein engineering and biologics manufacturing.
|
Sep 6 2011 | News
Biogen Idec today announced the company will acquire 100% of Dompe shares in its joint ventures in both Italy and Switzerland. This integration is part of Biogen Idec's and Dompe Group's broader strategy to focus on each company's respective core business.
|
Aug 9 2011 | News
Biogen Idec Inc. and Abbott Laboratories said Tuesday that multiple sclerosis drug candidate daclizumab worked better than a placebo at preventing a relapse of symptoms during a mid-stage clinical trial.
|
May 11 2011 | News
Patheon announced today the appointment of Michael E. Lytton
as Patheon's Executive Vice President, Corporate Development and Strategy and
General Counsel, effective immediately.
|
Apr 20 2011 | News
Genentech, a member of the Roche Group and Biogen Idec
announced today that the FDA has approved Rituxan(R) (rituximab), in combination
with corticosteroids, as a new medicine for adults with Wegener's
Granulomatosis (WG) and Microscopic Polyangiitis (MPA).
|
Apr 13 2011 | News
Amunix, Inc. today announced that it has entered into an
exclusive worldwide research collaboration and option agreement with Biogen
Idec to research and develop novel, fully-recombinant blood factors (Factors
IX, VIII and VIIa) with improved therapeutic properties.
|
Feb 22 2011 | News
POZEN Inc. today announced the appointment of Mark N. Matthews
as Vice President of Marketing and Sales. Mr. Matthews will be responsible for
driving the commercial strategy for all pipeline products beginning with
POZEN's lead product candidate, PA32540, a coordinated-delivery tablet of
enteric-coated aspirin and immediate-release omeprazole.
|
Jan 31 2011 | News
NEW YORK (AP) — Biogen Idec Inc. and Genentech said Friday that the FDA
has approved an additional use for blockbuster cancer drug
Rituxan as a first-line maintenance treatment for patients with
follicular
lymphoma, a cancer of the blood.
|